DZNE and Eisai team up

Research collaboration to fight neurodegenerative disorders

The German Center for Neurodegenerative Diseases (DZNE) and Eisai Co., Ltd. announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glia cells.

Photo

Image source: Shutterstock/Tatiana Shepeleva

DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases. The collaboration will incorporate DZNE’s expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.

We think that this collaboration will be able to accelerate creation of new treatments for neurodegenerative disorders, including those for Alzheimer’s and Parkinson’s

Pierluigi Nicotera

Prof. Pierluigi Nicotera, Chairman of the DZNE’s Executive Board commented: “We are pleased to have formed this collaboration with Eisai, which has an outstanding track record and a company-wide commitment to providing innovative treatments in the neurodegenerative disorders field. We think that this collaboration will be able to accelerate creation of new treatments for neurodegenerative disorders, including those for Alzheimer’s and Parkinson’s. The DZNE will contribute knowledge and technical expertise in studying disease processes combined with our translational, patient-oriented approach that involves close interaction between fundamental and clinical research.”

Dr. Teiji Kimura, Vice President, Chief Discovery Officer of the Eisai Neurology Business Group, commented: “Neurodegenerative diseases including AD comprise a disease area with high unmet medical needs. DZNE has many world-leading scientists in this field and we expect to create new disease-modifying therapies for those suffering from neurodegenerative disorders by conducting research for immune and metabolic incompetence in neurons and glia cells.”


Source: German Center for Neurodegenerative Diseases

17.03.2021

Read all latest stories

Related articles

Photo

From foe to friend?

Some Alzheimer’s plaques may be protective, not destructive

One of the characteristic hallmarks of Alzheimer’s disease (AD) is the buildup of amyloid-beta plaques in the brain. Most therapies designed to treat AD target these plaques, but they’ve largely…

Photo

Prevention research

These 10 risk factors must be tackled to prevent Alzheimer's

There are at least 10 risk factors that appear to have a significant impact on a person’s likelihood of developing Alzheimer’s disease that could be targeted with preventative steps, new research…

Photo

Dementia diagnostics

Lack of sleep might throw off Alzheimer’s test

A preliminary study has found that when young, healthy men were deprived of just one night of sleep, they had higher levels of tau, a biomarker for Alzheimer’s disease, in their blood than when…

Related products

mediaire – mdbrain

Artificial Intelligence

mediaire – mdbrain

mediaire GmbH
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter